A detailed history of China Universal Asset Management Co., Ltd. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 16,087 shares of BEAM stock, worth $361,957. This represents 0.04% of its overall portfolio holdings.

Number of Shares
16,087
Previous 9,906 62.4%
Holding current value
$361,957
Previous $232,000 69.83%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$22.57 - $33.14 $139,505 - $204,838
6,181 Added 62.4%
16,087 $394,000
Q2 2024

Jul 19, 2024

SELL
$21.22 - $32.66 $127,595 - $196,384
-6,013 Reduced 37.77%
9,906 $232,000
Q1 2024

Apr 29, 2024

BUY
$23.46 - $45.07 $146,671 - $281,777
6,252 Added 64.67%
15,919 $526,000
Q4 2023

May 21, 2024

SELL
$17.69 - $30.76 $110,597 - $192,311
-6,252 Reduced 39.27%
9,667 $263,000
Q4 2023

Jan 23, 2024

BUY
$17.69 - $30.76 $130,817 - $227,470
7,395 Added 325.48%
9,667 $263,000
Q3 2023

May 21, 2024

BUY
$23.01 - $32.46 $23,861 - $33,661
1,037 Added 83.97%
2,272 $54,000
Q3 2023

Oct 30, 2023

BUY
$23.01 - $32.46 $23,861 - $33,661
1,037 Added 83.97%
2,272 $55,000
Q2 2023

May 21, 2024

BUY
$29.32 - $35.99 $527 - $647
18 Added 1.48%
1,235 $39,000
Q2 2023

Jul 27, 2023

BUY
$29.32 - $35.99 $527 - $647
18 Added 1.48%
1,235 $39,000
Q1 2023

May 21, 2024

BUY
$30.15 - $48.79 $7,989 - $12,929
265 Added 27.84%
1,217 $37,000
Q1 2023

Apr 27, 2023

BUY
$30.15 - $48.79 $7,989 - $12,929
265 Added 27.84%
1,217 $37,000
Q4 2022

May 21, 2024

SELL
$36.73 - $51.6 $549,737 - $772,297
-14,967 Reduced 94.02%
952 $37,000
Q4 2022

Jan 31, 2023

BUY
$36.73 - $51.6 $2,093 - $2,941
57 Added 6.37%
952 $37,000
Q3 2022

Oct 21, 2022

BUY
$39.79 - $70.31 $35,612 - $62,927
895 New
895 $43,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.58B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.